Simpa S. Salami, M.D., M.P.H. is a fellowship-trained, board-certified Urologic Oncologist and Associate Professor of Urology at the University of Michigan. He obtained his MD from the College of Medicine, University of Ibadan, Nigeria. Thereafter, he graduated from the Master of Public Health program at Harvard University. He subsequently pursued his General Surgery internship at the Brigham and Women’s Hospital in Boston, Urology residency at Hofstra Northwell Health School of Medicine in New York, and Urologic Oncology fellowship at the University of Michigan in Ann Arbor. Dr. Salami is a translational surgeon-scientist whose research interests are in early detection and staging of prostate and kidney cancer. He seeks to leverage novel imaging, machine learning, and next generation sequencing and molecular profiling approaches to characterize cancer heterogeneity and tumor multifocality. The goal of his research is to develop novel cancer biomarkers and elucidate optimal paradigms for early detection of urologic cancers, risk stratification, prognostication, and prediction of treatment response. Dr. Salami is a recipient of the Harvard University Presidential Scholar Award, Prostate Cancer Foundation Young Investigator Award, American Urological Association (AUA) Urology Care Foundation (UCF) Research Scholar Award, AUA UCF Rising Stars in Urologic Research Award, and Harold Amos Medical Faculty Development Fellowship Award. He has served on a number of national guideline committees, such as the AUA Prostate Cancer Early Detection Guidelines, the NCCN Prostate Cancer Early Detection Guidelines, and the Society of Nuclear Medicine and Imaging PSMA Appropriate Use Criteria Working Group. His research is supported by multiple sources and includes funding from the Department of Defense, National Cancer Institute, and the Prostate Cancer Foundation.